Simulations Plus - 500 Beiträge pro Seite

[R-BgO]

Simulations Plus Reports Second Quarter FY2011 Financial Results

Company Reports Record $0.06/share for Quarter, $0.09/share for First Six Months

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its second quarter of fiscal year 2011 ended February 28, 2011 (2QFY11).

2QFY11 highlights compared with 2QFY10:

Consolidated revenues up 13.5% to record $3.349 million from $2.949 million
Pharmaceutical software and services revenues up 17.7% to $2.621 million from $2.227 million
Words+ subsidiary revenues up 0.7% to $728,000 from $723,000
Gross profit up 15.6% to $2.601 million from $2.249 million
SG&A decreased 10.0% to $0.980 million from $1.089 million
R&D expense increased 1.0% to $255,000 from $252,000
Income before income taxes up 43.2% to $1.394 million from $0.974 million
Net income up 41.6% to $907,000 from $641,000
Diluted earnings per share up 44.6% to $0.06 from $0.04
First six months FY11 (6moFY11) highlights compared with 6moFY10:

Consolidated revenues increased 14.4% to record $6.161 million from $5.387 million
Pharmaceutical software and services revenues up 17.9% to $4.672 million from $3.961 million
Words+ subsidiary revenues up 4.4% to $1.489 million from $1.425 million
Gross profit up 14.5% to $4.671 million from $4.079 million
SG&A decreased 2.4% to $2.043 million from $2.093 million
R&D expense decreased 9.9% to $463,000 from $513,000
Income before income taxes up 35.7% to $2.219 million from $1.635 million
Net income up 37.7% to $1.475 million from $1.071 million
Diluted earnings per share $0.09, an increase of 39.1% from $0.06
Cash decreased to $8.76 million from $9.63 million at the beginning of the fiscal year due to cash used for the repurchase of Company shares
Ms. Momoko Beran, chief financial officer of Simulations Plus, said: "Once again, we''re pleased to report a record quarter for both revenues and profitability. As we have noted in the past, earnings growth outpaces revenue growth because of the margins on the pharmaceutical software and services side of the business. Cash at the end of 2QFY11 was $8.759 million compared to $8.873 million at the end of 1QFY11, and compared to $9.632 million at the beginning of the fiscal year. We used $1.202 million of our cash to repurchase 397,680 shares during the first quarter and another $865,000 to repurchase 278,159 shares in the second quarter, which ended the second phase of our authorized share repurchase program. Over a period of two years for both phases of our repurchase program, we repurchased a total of 2,022,731 shares at an average price of $2.05 at an expenditure of $4,200,810. Shareholders'' equity at the end of the second quarter was $12.655 million compared to $13.045 million at the beginning of our fiscal year on September 1, 2010, while shareholders'' equity per share decreased slightly from $0.79 to $0.78 per diluted share. Now that the share repurchases have ended, we will not be using cash for that purpose unless the Board of Directors decides to institute a third phase. At this time, the board has not indicated its intent to do so."

Walt Woltosz, chairman and chief executive officer, added: "Our sustained growth and continued record quarter-over-quarter performance are the result of providing the very best in our product areas, an aggressive marketing and sales program, world-class customer support, and frugal expense management. Although we''ve had little recent success in identifying appropriate acquisitions, we continue to look and we are increasing our recruiting efforts to expand our Life Sciences staff. This will enable us to more rapidly pursue more of the organic growth opportunities we''ve identified. These opportunities are both in the area of increased capabilities of our existing pharmaceutical software and services, and in new product developments. The recently announced releases of ADMET Predictor™ 5.5, MedChem Studio™ 2.0, and our new MedChem Designer™ software are evidence of the continued product enhancements and new product developments going on at Simulations Plus. We remain committed to providing only the best in each of our product areas and to expanding our offerings going forward."

[Tamakoschy]

Antwort auf Beitrag Nr.: 41.385.269 von R-BgO am 18.04.11 19:33:05

Press Release Source: Simulations Plus, Inc. On Thursday June 2, 2011, 8:00 am EDT

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ:SLP - News), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its third fiscal quarter of fiscal year 2011, ended May 31, 2011 (3QFY11).

Ms. Momoko Beran, chief financial officer of Simulations Plus, stated: “In accordance with our policy to release timely financial information to our shareholders, we are releasing preliminary revenues for 3QFY11. Net income will not be known until income taxes have been determined and our auditors review our Quarterly Report on Form 10Q for 3QFY11. We expect to file our 10Q with the U.S. Securities and Exchange Commission on or before the July 15, 2011 deadline.”

Preliminary results for the quarter:

This was the Company’s 15th consecutive profitable quarter
Preliminary revenues for the pharmaceutical software and services portion of the business increased to $2.643 million, compared to $2.325 million in 3QFY10
This represents an increase of 13.7% over 3QFY10
Approximately 14.3% of 3QFY11 pharmaceutical software and services business was from new customers
Preliminary revenues for the Words+ subsidiary were $0.800 million compared to $0.794 million in 3QFY10, an increase of 0.8%
Consolidated preliminary revenues for 3QFY11 were $3.442 million compared to $3.119 million in 3QFY10
This represents an increase of 10.4% compared to 3QFY10
Cash at the end of the quarter was $9.7 million

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “We continue to expand our customer base, with over 30 new software customers added so far this fiscal year, including two in China. The increase in adoption of simulation and modeling software by smaller companies demonstrates the trend we’ve been seeing in recent years that the market for simulation and modeling software has potential well beyond the giants of the industry who were the early adopters. We believe the total potential market may be on the order of 1,000-2,000 companies in the pharmaceutical industry alone. In addition to our new software customers, we’ve also added consulting customers. We offer world-class expertise in drug absorption, pharmacokinetics, and pharmacodynamics to our consulting customers, who range from top 5 pharma companies to numerous smaller companies worldwide. We’ve been steadily interviewing and hiring to expand our Life Sciences staff, with one new Ph.D. starting yesterday and another starting August 1. We will continue this expansion for the foreseeable future in order to address a number of market opportunities we’ve identified for organic growth.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. Our wholly owned subsidiary, Words+, Inc., provides assistive technologies to persons with disabilities, including the computerized communication system used by world-famous theoretical astrophysicist Professor Stephen Hawking. For more information, visit our Web sites at www.simulations-plus.com and www.words-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

Contact:

Simulations Plus Investor Relations
Ms. Renée Bouché, 661-723-7723
[e-mail]
or
Hayden IR
Mr. Cameron Donahue, 651-653-1854
[e-mail]

[R-BgO]

Investor News
Simulations Plus Reports Preliminary Revenues for Fourth Fiscal Quarter and FY2011
09/07/11
Simulations Plus Reports Preliminary Revenues for Fourth Fiscal Quarter and FY2011

Pharmaceutical Software and Services Revenues Increase 6.9% for 4 th Quarter, up 14.7% for the Fiscal Year

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP - News ), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its fourth fiscal quarter of fiscal year 2011, ended August 31, 2011 (4QFY11), and for the entire fiscal year 2011 (FY11).

Ms. Momoko Beran, chief financial officer of Simulations Plus, stated, “In accordance with our policy to release timely financial information to our shareholders, we are releasing preliminary revenues for 4QFY11 and for the entire fiscal year 2011. Net income will not be known until income taxes have been determined and our auditors review our Annual Report on Form 10K for FY11. We expect to file our 10K with the U.S. Securities and Exchange Commission on or before the November 30, 2011 deadline.”

Preliminary results for the quarter:

This was the Company’s 16th consecutive profitable quarter, and the 38th of the last 40 quarters.
Preliminary revenues for the pharmaceutical software and services portion of the business increased to $1.426 million, compared to $1.334 million in 4QFY10.
This represents an increase of 6.9% over 4QFY10.
Approximately 24% of 4QFY11 pharmaceutical software and services business was from new customers.
Preliminary revenues for the Words+ subsidiary were $0.692 million compared to $0.872 million in 4QFY10, a decrease of 20.6%.
Consolidated preliminary revenues for 4QFY11 were $2.118 million compared to $2.206 million in 4QFY10, a decrease of 4.0% compared to 4QFY10.
Cash at the end of the quarter was $10.115 million.
Preliminary results for the entire fiscal year:

Preliminary revenues for the pharmaceutical software and services portion of the business increased to $8.738 million in FY11, compared to $7.621 million in FY10.
This represents an increase of 14.7% over FY10.
Approximately 20.5% of FY11 pharmaceutical software and services business was from new customers.
Preliminary revenues for the Words+ subsidiary were $2.981 million compared to $3.091 million in FY10, a decrease of 3.6%.
Consolidated preliminary revenues for FY11 were $11.719 million compared to $10.712 million in FY10, an increase of 9.4% compared to FY10.
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “Our pharmaceutical software and services business continues to be strong, increasing nearly 15% for the fiscal year compared to last year. Although this was a new record fourth quarter for pharmaceutical revenues, the decrease in revenue from our Words+ subsidiary pulled the total below last year’s fourth quarter. On the pharmaceutical side, our revenues last year included approximately $343,000 from funded software development collaborations and our SBIR Grant from the NIH. All of those efforts were successfully completed prior to the beginning of the fourth quarter, thus this year no such revenues were available. The fact that we were able to increase pharmaceutical revenues by 6.9% indicates that we not only replaced the $343,000 in revenues from collaborations with increases in software licenses and services, we added yet another 6.9% in incremental revenues. Since software licenses are annual, and our renewal rate consistently runs above 90%, we expect that the continued growth in software licenses and consulting services will now be added to a lasting base rather than the time-limited revenues from funded collaborations.”

Jeff Dahlen, president of Words+, added: “We often see variation in revenues from month to month, and this quarter had two weak months in the same quarter. Coming up against our best quarter in the last three years (4QFY10) makes this quarter suffer even more by comparison. During FY 2011, Words+ responded to significant changes in technology, buying preferences, and internet service delivery expectations. Our major development effort has been the EyePro GS, which was released shortly before the end of the quarter. We have begun taking orders, but with the long buying cycles in this industry, it will take some time before the full benefit of the EyePro GS is felt. In the long run, the EyePro GS adds to our existing line of eye tracking solutions, so that our dealers can enter into a competitive sales situation with the widest range of solutions of any manufacturer. EyePro GS also has better margins than all of the other solutions in our eyegaze family. Eye tracking continues to be a specialized area that allows us the markups we need to support R&D. We also introduced the Conversa CV and CVX toward the end of the quarter and upgraded most products to Windows 7. We have a number of new products in the works, and the release of the EyePro GS frees up engineering resources to move those projects forward quicker. Remote internet-based support and training was in place and growing for all of FY 2011. We had significant attrition in our dealer network and some of our key dealers were less active during the summer and we are aggressively adding dealers in response. We expect, through the changes we made in FY 2011 and continued improvements in product development and service delivery, that FY 2012 revenues will increase compared to FY 2011 and contribute to the Simulations Plus bottom line.”

[R-BgO]

January 18, 2012

Simulations Plus Reports First Quarter FY2012 Financial Results

Net sales increase 9.6% to first quarter record $2.248 million; Net income up 30.9% to $755,000

LANCASTER, CA, January 18, 2012 – Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2012 ended November 30, 2011 (1QFY12). Results below are reported for continuing operations (without the discontinued operations of the Company’s former Words+ subsidiary), except as noted.

1QFY12 highlights compared with 1QFY11:
· Net sales increased 9.6% to first-quarter record $2.248 million from $2.050 million
· Gross profit increased 11.7% to $1.896 million from $1.697 million
· SG&A increased 2.0% to $0.700 million from $0.686 million, but decreased as a percent of revenues to 31.1% from 33.5%
· R&D expenditures increased 14.9% to $454,000 from $395,000
· Income before taxes increased 27.6% to $1.064 million from $0.834 million
· Net income from continuing operations increased 30.9% to $755,000 from $577,000, and including the proceeds from the sale of Words+, partially offset by the discontinued operations of Words+, net income increased 71.1% to $971,000 from $567,000
· Total diluted earnings per share, including discontinued operations, increased 100% to $0.06 from $0.03
· Diluted earnings per share for only the continuing operations up 67% to $0.05 from $0.03

Ms. Momoko Beran, chief financial officer of Simulations Plus, said: “This was a very busy quarter, with increased Selling, General and Administrative expenses related to the attempted acquisition of assets of Entelos in bankruptcy court as well as the sale of our former Words+ subsidiary. Despite these nonrecurring expenses, we’re pleased to report these results that show continued strong top- and bottom-line performance, including record first-quarter revenue and a 30.9% increase in net income. Cash at the end of 1QFY12 was up 42.7% to $12.662 million compared to $8.873 million at the end of 1QFY11, and up 26.1% from $10.037 million at the beginning of the quarter. Shareholders’ equity increased 20.9% to $15.088 million compared to $12.482 million in 1QFY11.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “Simulations Plus continues to demonstrate sustained strong growth in sales and even stronger sustained growth in net income. The increased sales and net income from our continuing operations for this new record first quarter are enhanced even more with the small profit from the sale of our former Words+ subsidiary. Accomplishing that sale was a major effort over the past half year that leaves us now with a focused business and without the losses that occurred all too often in the subsidiary that reduced the overall financial performance of the company. It’s worthy to note that as we compare this first quarter with last year, we had about $67,000 in grant revenues last year that we did not have this year, so comparing software and consulting revenue growth alone increased by about 13.4% rather than the 9.6% shown above. Our cash position is stronger than ever, and the board of directors is evaluating the potential effects of either another share repurchase program, an ongoing dividend with an attractive yield, or some combination of the two that could be accomplished without using all of our positive cash flow so that net cash would not decrease. Of course, there can be no assurances that the board will approve a share repurchase or dividend, but the board is committed to creating shareholder value.”

Woltosz continued: “We continue to evaluate acquisition opportunities as we can identify any that would fit our business model. The difficulty we’ve had in finding appropriate acquisition opportunities, i.e., those that would not require an inordinate amount of time and money to realize a reasonable return on investment, is a matter of record. We continue to grow organically and to pursue our aggressive marketing and sales program, which has yielded the growth that can be seen in this report. We are also making progress on our NCE (new chemical entity) project for malaria, with compounds in synthesis, and we expect to have samples ready for testing in the coming quarter.”

[R-BgO]

Board of directors declares an ongoing quarterly dividend of $0.05 per share

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has voted to distribute an ongoing quarterly cash dividend of $0.05 per share to its shareholders beginning with the current fiscal year. The first dividend payment will be distributed on Thursday, March 1, 2012, for shareholders of record as of Tuesday, February 21, 2012.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “As we announced during the last conference call, the board of directors has been considering the use of our cash reserves. After careful consideration that included information provided through a study by an outside firm, the board has concluded that a dividend is appropriate at this time. To that end, the Company will begin paying an ongoing quarterly dividend of five cents ($0.05) per share. This dividend will be in lieu of a share repurchase.”

The factors the board considered in making this decision included, but were not limited to:

The Company’s cash position continues to grow at a pace management believes will be sustained for the foreseeable future. Cash at the end of our first quarter was $12.66 million, as compared to $8.9 million at 11/30/2010. Cash as of February 9, 2012, was approximately $13.17 million.
In spite of consistent, concerted efforts, and contacts made with numerous potential acquisitions, the Company has not yet been able to identify anything appropriate for the Company’s investment. This effort continues and will not be affected by the dividend.
The Company has spent approximately $4 million over the last 2-3 years repurchasing shares. At this time, the board does not believe further repurchases are as beneficial to shareholders as a cash dividend.

[Push Daddy]

und wieder ein neues Jahreshoch. Setzt jemand von euch SL?

[Push Daddy]

Mal einen kleinen Chart. Nicht zu vergessen: Dividendenrendite etwas über 4 % ( brutto )

[R-BgO]

heute um 150% aufgestockt

[R-BgO]

Q4-Zahlen: http://www.simulations-plus.com/PressReleaseDetails.aspx?pID…

[R-BgO]

Simulations Plus Announces Accelerated Quarterly Cash Dividend
Company declares accelerated cash dividend of $0.14 per share

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. ( SLP ), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has decided to accelerate a portion of the expected dividend payments for 2013, in light of uncertainty surrounding taxes on dividends.

The Board of Directors declared its next ongoing quarterly cash dividend of $0.05 per share. In addition, the Board of Directors decided to pay a $0.03 per share portion of the intended $0.05 per share dividend for the following three quarters to its shareholders. This accelerated payment will be distributed on Friday, December 28, 2012, for shareholders of record as of Monday, December 24, 2012.

Ms. Momoko Beran, chief financial officer of Simulations Plus, said: “The board has decided, as many other public boards have, that to take advantage of the federal income tax rates currently in effect and due to expire on December 31, it is in the best interests of the majority of shareholders to receive dividend distributions during the current tax year. The board will continue to review the Company’s dividend policy, considering tax rates, policies, and the Company’s financial performance.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “Some companies are distributing as much as eight quarters of dividends in advance, but their yields are more typically around two percent, while ours is more than double that. By distributing a portion of the second through fourth quarter intended dividends now, we benefit current shareholders. By maintaining the remaining portion for those quarters as intended distributions for next year, we expect to maintain interest in the stock for investors who seek dividends at a rate competitive with most other dividend-paying companies. It should be noted that the board of directors always has the option of increasing, decreasing, or eliminating future dividend payments in accordance with the Company’s priorities for its use of cash or changes in tax laws, so that there can be no assurances that future dividends will be paid, and if they are, what the actual amounts might be.”

[R-BgO]

December 7, 2012

Simulations Plus Reports Preliminary Revenues for
First Fiscal Quarter FY2013

Revenues Increase 1.9% for New Record 1st Quarter

LANCASTER, CA , December 7, 2012 – Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its first fiscal quarter of fiscal year 2013, ended November 30, 2012 (1QFY13).

Ms. Momoko Beran, chief financial officer of Simulations Plus, stated, “In accordance with our policy to release timely financial information to our shareholders, we are releasing preliminary revenues for 1QFY13. Net income will not be known until income taxes have been determined and our auditors review our Quarterly Report on Form 10-Q. We expect to file our 10-Q with the U.S. Securities and Exchange Commission on or before the January 14, 2013 deadline.”

Preliminary results for the quarter:
· This was the Company’s 21st consecutive profitable quarter, and the 43rd of the last 45 quarters
· Preliminary revenues increased to $2.290 million, compared to $2.248 million in 1QFY12
· This represents an increase of 1.9% over 1QFY12 and is a new record 1st quarter
· Approximately 11% of revenues came from new software licenses
· Approximately 9% of revenues came from consulting studies and collaborations
· Cash as of November 30, 2012 was $11.4 million

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said, “Fiscal year 2013 has had a somewhat bumpy start but, with the combined revenues from new software licenses and consulting services more than offsetting approximately $450,000 in software licenses that were not renewed due to facility closures and consolidations, we have set yet another record for first fiscal quarters and quarter-over-quarter result. We remain financially very strong, with our cash at nearly $11.5 million after paying out over $3 million in dividends in the past year and $1.1 million in taxes last month, and we continue to have no debt.”

Investor Conference Presentation

The Company’s chairman and chief executive officer, Walt Woltosz, will be presenting at the Sidoti Semi-Annual Micro-Cap Conference taking place on January 7, 2013, at New York City’s Grand Hyatt Hotel. Mr. Woltosz will be presenting at 11:20 a.m., and he will also be available for one-on-one meetings throughout the day.

[R-BgO]

Dividende auf 4c erhöht, Jahreszahlen können jeden Tag kommen...

[Haettsch]

+5MioUSD profitabler Umsatz für 7Mio (Cash + ca. 4,5% Aktien aus KE)
http://finance.yahoo.com/news/simulations-plus-acquire-cogni…

[R-BgO]

Simulations Plus Reports Preliminary Revenues for Fourth Fiscal Quarter FY2014

Company Reports Record Fourth Quarter and Fiscal Year Revenues
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its fourth fiscal quarter and fiscal year 2014, ended August 31, 2014 (4QFY14).

Mr. John R Kneisel, chief financial officer of Simulations Plus, stated: “In accordance with our policy to release timely financial information to our shareholders, we are releasing preliminary revenues for 4QFY14. Net income will not be known until income taxes have been determined and our auditors review our Annual Report on Form 10-K. We expect to file our 10-K with the U.S. Securities and Exchange Commission on or before the November 30, 2014 deadline.”


Preliminary results for the quarter:

This was the Company’s 28th consecutive profitable quarter
Preliminary revenues increased 15.1% to $1.805 million, compared to $1.568 million in 4QFY13
Approximately 25.5% of revenues came from new software licenses
Approximately 5.5% of revenues came from consulting studies and collaborations
Cash as of September 3, 2014 was $6.8 million after a dividend distribution of approximately $800,000 was made on August 11, 2014 and a $2.080 million payment made as part of the acquisition of Cognigen Corporation that was closed on September 2, 2014


Preliminary results for the fiscal year:

This was the company’s 7th consecutive profitable year, and set a new record for fiscal year revenues
Preliminary revenues increased 11.9% to $11.268 million, compared to $10.071 million in FY2013
Approximately 18.6% of revenues came from new software licenses
Approximately 3.9% of revenues came from consulting studies and collaborations


John DiBella, vice president for marketing and sales of Simulations Plus, said: “This new record for fourth fiscal quarter revenues is likely to be eclipsed by a substantial amount going forward as a result of our just-completed acquisition of Cognigen Corporation. In addition to the sustained growth of Simulations Plus over more than 10 years, we will now be adding revenues from our Cognigen division. Needless to say, this is an exciting time for both Simulations Plus and Cognigen.”

Ted Grasela, newly appointed president of Simulations Plus, added: “I am very pleased to have been appointed president of Simulations Plus and Cognigen, and I’m encouraged by the strong preliminary results we are reporting today. I’m looking forward to fiscal year 2015 and working with the Simulations Plus and Cognigen teams to continue the excellent history of growth for Simulations Plus.”

- See more at: http://www.simulations-plus.com/PressReleaseDetails.aspx?pID…

[R-BgO]

Dow Chemical Licenses Simulations Plus Software to Assist with Toxicology and Environmental Research

October 27, 2014

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for discovery and development, announced that The Dow Chemical Company (NYSE: DOW) has licensed both its best-in-class GastroPlus™ and ADMET Predictor™ software programs.

John DiBella, vice president of marketing and sales for Simulations Plus, said, “Dow again demonstrates its foresight by incorporating our modeling and simulation technology to assist with their toxicology and environmental research activities. There is an appreciation for how the tight integration of our Quantitative Structure-Activity Relationship (QSAR) and Physiologically-Based Pharmacokinetic (PBPK) modeling tools streamline the process of generating in vivo simulation results through different administration routes. We look forward to working with Dow scientists in these areas and identifying potential areas for collaboration. This announcement, following closely on the news that the U.S. EPA has added licenses of our software, provides further evidence that our programs have applications across several industries.” - See more at: http://www.simulations-plus.com/PressReleaseDetails.aspx?pID…

[R-BgO]

per Q3 lag man +20% ggü VJ: http://www.simulations-plus.com/PressReleaseDetails.aspx?pID…

[R-BgO]

FDA’s Office of New Drug Products Places Order for 50 Additional Licenses to GastroPlus™

Additional Licenses Required to Meet Increasing Number of Submissions Utilizing GastroPlus

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), the leading provider of consulting services and software for pharmaceutical discovery and development, today announced that the U.S. Food and Drug Administration’s (FDA) Office of New Drug Products, Division of Biopharmaceutics has placed an order for 50 additional licenses to the Company’s GastroPlus™ software. This brings to 70 the total number of GastroPlus licenses in use at the FDA. The licenses are spread across various divisions, including the Office of Generic Drugs, Center for Veterinary Medicine, Office of Clinical Pharmacology, and the National Center for Toxicological Research.

John DiBella, vice president of marketing and sales for Simulations Plus, said, “We are very pleased with the expanding use of our software products by regulatory agencies. The FDA Office of Generic Drugs has purchased 10 licenses to GastroPlus for many years. One of the reasons for an order for additional licenses of this magnitude is to meet the needs of other FDA divisions to review an increasing number of regulatory submissions referencing GastroPlus modeling. Scientists at the FDA want to understand how they can encourage more use of the software program to address questions related to complex drug product behaviors.”

Simulations Plus also recently announced that the company has been awarded a second cooperative agreement from the FDA for $200,000 per year for up to three years. This award is in addition to another project the company was awarded by the FDA last year, and which was recently renewed for the second year. This new project is for “Development of PBPK simulations for long-acting injectable microspheres.”

Dr. Ted Grasela, president of Simulations Plus and its wholly owned subsidiary, Cognigen, said, “We are pleased to build on our relationships with the FDA and industry-wide recognition of the value of our software products. The FDA continues to explore new ways of utilizing modeling and simulation in all aspects of research and development, and this is reflected in the need for additional licenses.”

Views expressed in this press release do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.

[R-BgO]

Simulations Plus Reports First Quarter FY2016 Financial Results

Jan. 14, 2016 21:01 UTC



Consolidated net revenues up 18.4%; net income increased 109%

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its first quarter of fiscal year 2016, the period ended November 30, 2015 (1QFY16).

1QFY16 highlights compared with 1QFY15:

Net revenues increased 18.4%, or $752,000, to a new record $4.84 million from $4.09 million
Gross profit increased 21.6% to $3.76 million from $3.09 million
SG&A was $1.68 million, a decrease of $403,000, or 19.4%, from $2.08 million
Income before taxes increased $971,000, or 30.1%, to $1.72 million from $746,000
Net income increased $578,000, or 109%, to $1.11 million from $529,000
Diluted earnings per share increased $0.03 to $0.06 from $0.03 per share

John Kneisel, chief financial officer, said: “This quarter is the first truly comparative period since the Company acquired Cognigen Corporation at the beginning of our 2015 fiscal year. It reflects earnings as anticipated from the acquisition as well as quarterly expenses unencumbered by acquisition costs. Last year’s first quarter (1QFY15) operating income was substantially affected by approximately $400,000 in one-time fees and expenses that were incurred for the acquisition. We continue to maintain our strong financial position with current cash balances of approximately $7.8 million and no loans.”

Ted Grasela, president of the Company, added: “We continue to offer new and expanded consulting services to clients of both companies. In addition, software development activities have continued apace and exciting opportunities are emerging as our scientists gain cross-disciplinary experience during our collaborations.”

John DiBella, vice president for marketing and sales for Simulations Plus, said: “The positive trend of strong software sales and increasing requests for our consulting services continued in 1QFY16. The number of software units licensed saw a 29% increase compared to 1QFY15, which was driven by robust renewal rates and 23 new organizations, or new departments at existing organizations, now utilizing our technology. Education remains a key focus for us in 2016, as we have an aggressive workshop schedule planned for the U.S., Europe, and Asia to allow us to train more scientists on the applications of our technology. This, coupled with new releases of all major software products expected in FY16, gives us confidence in our ability to continue expanding our client base. In addition to our vigorous marketing and sales activities in 1QFY16, we introduced a unified Simulations Plus brand to better present our comprehensive offering of powerful software and consulting expertise, which we believe will resonate across different departments, companies, and markets. We will be embarking on a website redesign project in 2016 to support this effort.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “Fiscal year 2016 is off to a very good start with this record first quarter. I am particularly excited about the upcoming release of our new PKPlus™ software, which we believe will have a significant impact on revenues and earnings later in FY16. I’m also encouraged by the contacts we’ve been making in the aerospace industry regarding the products we’ve been developing for use in the aerospace industry. These products use our artificial neural network ensemble modeling engine and we are pursuing customers and funding to develop customized tools and applications in this new market.”

- See more at: http://www.simulations-plus.com/PressReleaseDetails.aspx?pID…

[R-BgO]

April 13, 2016 20:01 UTC

Simulations Plus Reports Second Quarter FY2016 Financial Results

Record second quarter as revenues grow 12.9%, net income up 18%

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its second quarter of fiscal year 2016, the period ended February 29, 2016 (2QFY16).

2QFY16 highlights compared with 2QFY15:

Net revenues increased 12.9%, or $590,000, to $5.16 million from $4.57 million
Gross profit increased 13.3%, or $457,000, to $3.90 million from $3.44 million
SG&A increased 7.2%, or $115,000, to $1.72 million from $1.61 million
Income before taxes increased 17.1%, or $247,000, to $1.69 million from $1.44 million
Net income was up by 18%, or $175,000, to $1.15 million from $970,000
Diluted earnings per share increased 16.9% to $0.066 from $0.057 per share


6moFY16 highlights compared with 6moFY15:

Net revenues increased 15.5%, or $1.34 million, to $10 million from $8.66 million
Gross profit increased 18%, or $1.17 million, to $7.66 million from $6.48 million
SG&A decreased 6.3%, or $228,000, to $3.4 million from $3.63 million
R&D expenditures increased 8.8%, or $110,000, to $1.36 million from $1.25 million in 6moFY15
In 6moFY16, $545,000 was capitalized and $813,000 was expensed
In 6moFY15, $631,000 was capitalized and $633,000 was expensed
Income before taxes increased 55.6%, or $1.22 million, to $3.41 million from $2.19 million
Net income increased 50.2%, or $753,000, to $2.25 million from $1.5 million
Diluted earnings per share increased 49.0% to $0.131 per share from $0.088 per share


John Kneisel, chief financial officer of Simulations Plus, said: “We continue our nearly decade-long trend of consistent revenue and earnings growth. Cash is back up above $8 million after two dividend distributions totaling over $1.7 million. As announced earlier, we will use approximately $1.47 million in cash this fiscal year to make a payment to TSRL as part of the royalty agreement buyout announced in May 2014, and the final payment to the former shareholders of Cognigen Corporation to close out our acquisition of Cognigen that took place in September 2014. We expect our cash reserves to remain more than adequate after these disbursements, and we anticipate continuing our quarterly dividend distributions; although, such distributions are always at the discretion of the Board of Directors, which votes on them each quarter.”

John DiBella, vice president for marketing and sales of Simulations Plus, said: “At the halfway point of FY2016, we have maintained solid renewal rates for software licenses and continued growth in new license sales and consulting revenues. The marketing and sales staff and our scientists have supported our aggressive marketing and sales program with attendance and presentations at key scientific meetings, conducting training workshops and webinars, and providing the strong customer support that is a hallmark of Simulations Plus in the industry.”

Ted Grasela, president of Simulations Plus, added: “The addition of the recently announced 5-year, $4.7 million contract for data management and consulting services with a major research foundation will add significantly to the revenue growth of our Buffalo division. We believe this effort, which is based on our secure in-house computing cloud and our unique KIWI™ software platform, has the potential to lead to additional opportunities for such services with a number of other research organizations around the world. And we are now routinely providing physiologically based pharmacokinetics (PBPK) analysis to clinical pharmacology groups as we realize the expected synergies between our Lancaster and Buffalo divisions.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, concluded: “As John DiBella noted, we’re halfway through FY2016, with six-month results showing excellent continued revenues and earnings growth. Now we are beginning to perform on our 5-year contract and expecting the release of our newest software product, PKPlus™, along with updates to two other programs, in the third fiscal quarter. We’re excited about these developments and expect them to add to a strong finish to FY2016.”

[R-BgO]

habe den aktuellen Kursrückgang

zum Aufstocken genutzt

[R-BgO]

Antwort auf Beitrag Nr.: 52.432.662 von R-BgO am 18.05.16 18:12:10

Q3 soll morgen kommen

[R-BgO]

Antwort auf Beitrag Nr.: 52.826.473 von R-BgO am 13.07.16 17:58:04

July 14, 2016 20:01 UTC
Simulations Plus Reports Third Quarter FY2016 Financial Results

Record quarterly revenue, 9moFY16 diluted EPS increased 23% to a record $0.242 from $0.196

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its third quarter of fiscal year 2016 (3QFY16) and the first nine months of fiscal year 2016 (9moFY16), the period ended May 31, 2016.

3QFY16 highlights compared with 3QFY15:

Net revenues increased 1.2% to $6.01 million, an increase of $70,000 from $5.94 million
Gross profit was up 0.2% to $4.82 million, an increase of $8,000 from $4.81 million
SG&A was $1.68 million, an increase of 4.6% or $73,000 from $1.61 million
R&D expenditures were $617,000, an increase of $23,000, or 3.8% over $594,000
In 3QFY16, $269,000 was capitalized and $348,000 was expensed
In 3QFY15, $246,000 was capitalized and $348,000 was expensed
Income before taxes decreased 0.8% to $2.80 million, a decrease of $22,000 from $2.82 million
Net income increased 3.1% to $1.91 million, an increase of $57,000 from $1.85 million
Diluted earnings per share increased 2.1% to $0.111 from $0.108
9moFY16 highlights compared with 9moFY15:

Net revenues increased 9.7% to $16.01 million, an increase of $1.41 million from $14.60 million
Gross profit was up 10.4% to $12.47 million, an increase of $1.18 million from $11.29 million
SG&A was $5.08 million, a decrease of $154,000, or 2.9%, from $5.23 million
R&D expenditures were $1.974 million, an increase of $17,000, or 0.9% over $1.957 million
For 9moFY16, $814,000 was capitalized and $1.16 million was expensed
For 9moFY15, $976,000 was capitalized and $982,000 was expensed
Income before taxes increased 23.9% to $6.21 million, an increase of $1.2 million from $5.01 million
Net income increased 24.2% to $4.16 million, an increase of $810,000 from $3.35 million
Diluted earnings per share increased 23.1% to $0.242 from $0.196
John Kneisel, chief financial officer of Simulations Plus, said: “The Company continues to produce record financial results, with year-to-date sales up nearly 10% and net income increased by 24%, speaking to our operational efficiency and demonstrating the leverage inherent in our business model. The Company’s strong cash position enables continuing investment in software products while being able to reward shareholders by providing continuing quarterly dividends. As always, such distributions are at the discretion of the Board of Directors.”

John DiBella, vice president for marketing and sales of Simulations Plus, said: “While revenue growth for 3QFY16 was lower than our historical averages, it is compared with an exceptionally strong third quarter in FY15. We executed on several fronts and achieved the highest quarter in our history for both revenues and earnings. Software renewal rates exceeded 88% (accounts) and 96% (fees) for the quarter, and we added 16 new clients, with several coming from India. The first nine months of FY2016 have shown strong growth trends in both software and consulting services revenue, and along with the imminent release of our new PKPlus™ software, we have a full pipeline of new contracts keeping our experts busy as we move towards FY2017. We believe our aggressive marketing and training programs, coupled with positive underlying sales fundamentals, set us up nicely to end FY2016 on a strong note.”

Ted Grasela, president of Simulations Plus, added: “The recently announced 5-year, $4.7 million contract to expand and further develop the KIWI™ software platform for a major research foundation is expected to add significantly to the revenue growth of our Buffalo division. We believe this effort, which is based on our secure in-house computing cloud, has the potential to lead to additional opportunities for such services, both with this foundation and with pharmaceutical companies and other research organizations around the world. In addition, we are now routinely providing physiologically based pharmacokinetics (PBPK) analysis to clinical pharmacology groups as we have realized the expected synergies between our Lancaster and Buffalo divisions.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, concluded: “This month marks the 20th anniversary of Simulations Plus. Driving the evolution of the pharmaceutical industry over the past two decades from minimal use of simulation and modeling to widespread adoption by industry and regulatory agencies has been very satisfying. As John DiBella noted, our nine-month results demonstrate excellent continued revenues and earnings growth. Now we are beginning to perform on our five-year contract and expecting the release of our newest software product, PKPlus™, along with updates to GastroPlus™ and ADMET Predictor™, all in the fourth fiscal quarter. We’re excited about these developments and expect them to contribute to a strong finish to FY2016.”

[R-BgO]

Antwort auf Beitrag Nr.: 52.838.485 von R-BgO am 15.07.16 09:06:54

Geschäftsjahr ging gestern zuende

rechne mit 5-6 MUSD Gewinn und 22MUSD EK;

womit rechnet Ihr?

[R-BgO]

Antwort auf Beitrag Nr.: 53.182.977 von R-BgO am 01.09.16 12:51:14

Zahlen kamen gestern,

es sind 5 MUSD Gewinn und 23 MUSD EK geworden;


läuft gut

[R-BgO]

Antwort auf Beitrag Nr.: 53.679.915 von R-BgO am 12.11.16 12:43:28

Montag

sollen Q1-Zahlen kommen...

[R-BgO]

Antwort auf Beitrag Nr.: 54.022.592 von R-BgO am 06.01.17 09:42:15

Simulations Plus Reports First Quarter FY2017 Financial Results

Consolidated net earnings up 23.1% on 12% revenue increase

January 09, 2017


Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its first quarter of fiscal year 2017, the period ended November 30, 2016 (1QFY17).


1QFY17 highlights compared with 1QFY16:

Net revenues increased 12.0%, or $579,000, to a new first quarter record $5.42 million vs. $4.84 million

Gross profit increased 8.7% to $4.08 million from $3.76 million

SG&A was $1.86 million, an increase of $187,000 or 11.2%, from $1.68 million

SG&A as a percentage of revenues decreased slightly from 34.6% to 34.4%

Income before taxes increased $250,000 or 14.6%, to $1.97 million from $1.72 million

Net income increased $255,000 or 23.1%, to $1.36 million from $1.11 million

Diluted earnings per share increased 22% or $0.014, to $0.078 from $0.064 per share


John Kneisel, chief financial officer of Simulations Plus, said: “Fiscal year 2017 is starting out with good first quarter profits, bolstered by strong consulting revenues. Our ability to effectively leverage our operations is enabling us to grow our bottom line at nearly twice the pace we are growing revenues, driving a 22% improvement in earnings per share.”

Ted Grasela, Company president, added: “It is rewarding to see the increase in business from both existing and new clients. This represents recognition and appreciation for the quality and value of our technology and consulting services. We are aggressively looking to expand our staff to meet the growing demand for modeling and simulation consulting support and are recruiting additional software engineers to continue development of our PBPK modeling and pharmacometrics communication platforms in order to streamline model-based drug development activities and increase license sales.

John DiBella, vice president for marketing and sales of Simulations Plus, said: “The positive trend of solid software sales and increasing requests for our consulting services continued in 1QFY17. Software license revenue increased 7.2%, driven by robust renewal rates and 28 new organizations, or new departments at existing organizations, now utilizing our technology. Revenue from consulting services increased 21.1%, as we applied our technology and expertise in a wide range of projects and engaged with 13 new clients. Education remains a key focus for us in 2017, as we have scheduled workshops for the U.S., Europe, and Asia to allow us to train more scientists on the applications of our tools. This, coupled with new releases of all major software products expected in FY17, gives us confidence in our ability to continue expanding our client base.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, concluded: “Fiscal year 2017 is off to a very good start with this record first quarter. Both divisions delivered strong performance in this first quarter, and our Buffalo division is now generating significant new revenues from our five-year, nearly $5 million consulting contract with a major research foundation in addition to our typical consulting work in that division. Software sales continue to grow as the pharmaceutical industry continues to adopt simulation and modeling technology to improve productivity and reduce wasted R&D efforts on compounds that would have failed. We expect this trend to continue in 2017, and Simulations Plus is increasingly well-positioned to benefit from this trend.”

[Tamakoschy]

Antwort auf Beitrag Nr.: 54.044.893 von R-BgO am 09.01.17 23:35:11

Die Zahlen werden vom Markt gut aufgenommen. Heute schon 5 % im plus.

[R-BgO]

Antwort auf Beitrag Nr.: 54.051.007 von Tamakoschy am 10.01.17 16:58:16

habe mich jahrelang geärgert,

dass es -so dachte ich- nie Präsentationen gab;

heute gemerkt, dass es sie doch gibt und zwar als Bestandteil der Quicktime-files zu den CCs.



Bei der Gelegenheit zum ersten Mal einen solchen durchgehört und sehr positiv angetan von der Ruhe und Nüchternheit der Vortragenden.

Bekomme ein immer besseres Gefühl bei diesem Engagement.

Wenn der Markt groß genug wäre, dann kann hier noch ein 10- oder mehr bagger rauskommen.

[R-BgO]

Simulations Plus to Acquire DILIsym Services, Inc.

Accretive acquisition to expand Simulations Plus offerings by adding leading provider of drug-induced liver injury (DILI) software and consulting services

May 01, 2017


Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has entered into a Stock Purchase Agreement (the “Agreement”) with DILIsym Services, Inc. of Research Triangle Park, North Carolina.

Pursuant to the Agreement, upon closing, DILIsym Services, Inc. (“DILIsym Services”) will become a wholly owned subsidiary of Simulations Plus, Inc. (“Simulations Plus”) and will continue to operate under the DILIsym Services name. This accretive acquisition will result in the total number of Simulations Plus employees increasing from 68 to 79, and is expected to add more than $3 million to the revenues of the combined company in the coming fiscal year 2018.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said, “This is an exciting step forward for both Simulations Plus and DILIsym Services. The combination will significantly strengthen our software and consulting services efforts, and bolster our management team as well. I am pleased that the existing management team of DILIsym Services will remain with the company. The officers of DILIsym Services will be Dr. Brett Howell, who will serve as president, Dr. Scott Siler, who will serve as chief scientific officer, and Dr. Bud Nelson, who will serve as director of operations. In the aggregate, these three leaders have more than 50 years of relevant experience. I will remain as Chairman and CEO of Simulations Plus, overseeing all three divisions (Simulations Plus, DILIsym Services, and Cognigen Corporation). In addition, Professor Paul Watkins, M.D., of the University of North Carolina, internationally recognized as the foremost authority on drug-induced liver injury, will continue as the director of the DILI-sim Initiative Consortium and chairman of the Initiative’s Scientific Advisory Board. This consortium is an international group of twelve pharmaceutical companies that fund the ongoing development of the DILIsym® software.”

Dr. Brett Howell added, “Drug-induced liver injury (DILI) is a rare adverse drug reaction and is the leading cause for acute liver failure in the United States. It is also the most common factor that compels regulatory actions related to drugs, such as denial of approval or restriction of indications for using a drug. It is a prime area of concern for the U.S. Food and Drug Administration and other regulatory agencies worldwide. The DILIsym® software is the most advanced mechanistic mathematical model of drug-induced liver injury, simulating the mechanistic interactions and events from drug administration through the progression of liver injury and regeneration. DILIsym Services scientists have supported our customers to present results of DILIsym simulations to several regulatory agencies. We are excited to join Simulations Plus and take advantage of the various synergies that exist between the organizations.”

John Kneisel, chief financial officer of Simulations Plus, added, “We expect this deal will be immediately accretive to both revenues and earnings, and will not affect our ability to continue to distribute dividends. Of course, the Board of Directors determines the dividend each quarter and has the option of continuing, increasing, decreasing, or eliminating it at any time to meet the cash needs of the business.”

The Agreement

The Agreement calls for the acquisition of DILIsym Services by Simulations Plus with DILIsym Services becoming a wholly owned subsidiary of Simulations Plus following the closing of the acquisition, which is subject to final due diligence and other closing conditions. The closing date of the proposed acquisition is anticipated to be June 1, 2017.

Under the terms of the Agreement, Simulations Plus will pay the shareholders of DILIsym Services cash consideration of up to $10 million, comprised of $5 million up front plus an earn-out of up to an additional $5 million over the next three years, based on the profitability of the DILIsym Services division. The Agreement provides that $1 million of the total up-front consideration will be held back for 18 months to satisfy any indemnifiable claims that may arise pursuant to the terms of the Agreement.

Excel Partners, an investment bank with offices in New York and Los Angeles, acted as exclusive financial advisor to Simulations Plus in connection with this transaction. Procopio, Cory, Hargreaves & Savitch LLP served as legal counsel to Simulations Plus in connection with this transaction.

[R-BgO]

10k kam gestern,

knapp 6 MUSD Nettogewinn, Divi wurde auf 6c pro Quartal angehoben

[R-BgO]

Wachstum ging in Q1 weiter

[R-BgO]

Antwort auf Beitrag Nr.: 56.186.877 von R-BgO am 15.11.17 10:28:10

für 2017/18

waren es bereits knapp 9 MUSD

[R-BgO]

Antwort auf Beitrag Nr.: 59.325.341 von R-BgO am 29.11.18 12:56:23

WOOOW!